Business Description
Newron Pharmaceuticals SpA
NAICS : 325412
ISIN : IT0004147952
Description
Financial Strength
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.25 | |||||
Equity-to-Asset | -1.24 | |||||
Debt-to-Equity | -1.58 | |||||
Debt-to-EBITDA | -3.45 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -1.17 | |||||
Beneish M-Score | -3.63 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 14.6 | |||||
3-Year EBITDA Growth Rate | 15.6 | |||||
3-Year EPS without NRI Growth Rate | 12.4 | |||||
3-Year FCF Growth Rate | 17.3 | |||||
Future 3-5Y Total Revenue Growth Rate | 23.39 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
9-Day RSI | 0.1 | |||||
14-Day RSI | 1.27 | |||||
6-1 Month Momentum % | -22 | |||||
12-1 Month Momentum % | 50.48 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.73 | |||||
Quick Ratio | 3.73 | |||||
Cash Ratio | 2.27 | |||||
Days Sales Outstanding | 106.55 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | -6.52 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -215.4 | |||||
Net Margin % | -270.28 | |||||
FCF Margin % | -191.5 | |||||
ROA % | -68.04 | |||||
ROIC % | -71.97 | |||||
ROC (Joel Greenblatt) % | -720.7 | |||||
ROCE % | -136.6 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 141.82 | |||||
PS Ratio | 20 | |||||
EV-to-EBIT | -12.67 | |||||
EV-to-Forward-EBIT | 71.56 | |||||
EV-to-EBITDA | -12.84 | |||||
EV-to-Forward-EBITDA | 71.56 | |||||
EV-to-Revenue | 26.33 | |||||
EV-to-Forward-Revenue | 25.96 | |||||
EV-to-FCF | -13.67 | |||||
Price-to-Median-PS-Value | 0.68 | |||||
Earnings Yield (Greenblatt) % | -7.89 | |||||
FCF Yield % | -9.11 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with GREY:NWPHF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Newron Pharmaceuticals SpA Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 7.552 | ||
EPS (TTM) ($) | -1.116 | ||
Beta | -0.53 | ||
Volatility % | 81.2 | ||
14-Day RSI | 1.27 | ||
14-Day ATR ($) | 0.002816 | ||
20-Day SMA ($) | 9.36 | ||
12-1 Month Momentum % | 50.48 | ||
52-Week Range ($) | 5.22 - 12 | ||
Shares Outstanding (Mil) | 19.23 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Newron Pharmaceuticals SpA Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Newron Pharmaceuticals SpA Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Newron Pharmaceuticals SpA Frequently Asked Questions
What is Newron Pharmaceuticals SpA(NWPHF)'s stock price today?
When is next earnings date of Newron Pharmaceuticals SpA(NWPHF)?
Does Newron Pharmaceuticals SpA(NWPHF) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |